CANbridge Pharmaceuticals Inc. (HKG:1228)

Market Cap	57.74M
Revenue (ttm)	90.56M
Net Income (ttm)	-471.02M
Shares Out	424.56M
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,093,000
Average Volume	2,628,250
Open	0.1310
Previous Close	0.1330
Day's Range	0.1300 - 0.1480
52-Week Range	0.0950 - 0.5000
Beta	-0.36
RSI	47.37
Earnings Date	May 29, 2025

About CANbridge Pharmaceuticals

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible IBAT inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also engages in the development of CAN106, an anti-C5 mAb that has completed Phase I b clinical trial ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 67
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1228

Financial Performance

In 2024, CANbridge Pharmaceuticals's revenue was 85.10 million, a decrease of -17.27% compared to the previous year's 102.87 million. Losses were -442.62 million, 16.8% more than in 2023.

Financial numbers in CNY